Cargando…

Determining breast cancer biomarker status and associated morphological features using deep learning

BACKGROUND: Breast cancer management depends on biomarkers including estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (ER/PR/HER2). Though existing scoring systems are widely used and well-validated, they can involve costly preparation and variable interpretatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Gamble, Paul, Jaroensri, Ronnachai, Wang, Hongwu, Tan, Fraser, Moran, Melissa, Brown, Trissia, Flament-Auvigne, Isabelle, Rakha, Emad A., Toss, Michael, Dabbs, David J., Regitnig, Peter, Olson, Niels, Wren, James H., Robinson, Carrie, Corrado, Greg S., Peng, Lily H., Liu, Yun, Mermel, Craig H., Steiner, David F., Chen, Po-Hsuan Cameron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037318/
https://www.ncbi.nlm.nih.gov/pubmed/35602213
http://dx.doi.org/10.1038/s43856-021-00013-3
_version_ 1784693709807288320
author Gamble, Paul
Jaroensri, Ronnachai
Wang, Hongwu
Tan, Fraser
Moran, Melissa
Brown, Trissia
Flament-Auvigne, Isabelle
Rakha, Emad A.
Toss, Michael
Dabbs, David J.
Regitnig, Peter
Olson, Niels
Wren, James H.
Robinson, Carrie
Corrado, Greg S.
Peng, Lily H.
Liu, Yun
Mermel, Craig H.
Steiner, David F.
Chen, Po-Hsuan Cameron
author_facet Gamble, Paul
Jaroensri, Ronnachai
Wang, Hongwu
Tan, Fraser
Moran, Melissa
Brown, Trissia
Flament-Auvigne, Isabelle
Rakha, Emad A.
Toss, Michael
Dabbs, David J.
Regitnig, Peter
Olson, Niels
Wren, James H.
Robinson, Carrie
Corrado, Greg S.
Peng, Lily H.
Liu, Yun
Mermel, Craig H.
Steiner, David F.
Chen, Po-Hsuan Cameron
author_sort Gamble, Paul
collection PubMed
description BACKGROUND: Breast cancer management depends on biomarkers including estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (ER/PR/HER2). Though existing scoring systems are widely used and well-validated, they can involve costly preparation and variable interpretation. Additionally, discordances between histology and expected biomarker findings can prompt repeat testing to address biological, interpretative, or technical reasons for unexpected results. METHODS: We developed three independent deep learning systems (DLS) to directly predict ER/PR/HER2 status for both focal tissue regions (patches) and slides using hematoxylin-and-eosin-stained (H&E) images as input. Models were trained and evaluated using pathologist annotated slides from three data sources. Areas under the receiver operator characteristic curve (AUCs) were calculated for test sets at both a patch-level (>135 million patches, 181 slides) and slide-level (n = 3274 slides, 1249 cases, 37 sites). Interpretability analyses were performed using Testing with Concept Activation Vectors (TCAV), saliency analysis, and pathologist review of clustered patches. RESULTS: The patch-level AUCs are 0.939 (95%CI 0.936–0.941), 0.938 (0.936–0.940), and 0.808 (0.802–0.813) for ER/PR/HER2, respectively. At the slide level, AUCs are 0.86 (95%CI 0.84–0.87), 0.75 (0.73–0.77), and 0.60 (0.56–0.64) for ER/PR/HER2, respectively. Interpretability analyses show known biomarker-histomorphology associations including associations of low-grade and lobular histology with ER/PR positivity, and increased inflammatory infiltrates with triple-negative staining. CONCLUSIONS: This study presents rapid breast cancer biomarker estimation from routine H&E slides and builds on prior advances by prioritizing interpretability of computationally learned features in the context of existing pathological knowledge.
format Online
Article
Text
id pubmed-9037318
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-90373182022-05-20 Determining breast cancer biomarker status and associated morphological features using deep learning Gamble, Paul Jaroensri, Ronnachai Wang, Hongwu Tan, Fraser Moran, Melissa Brown, Trissia Flament-Auvigne, Isabelle Rakha, Emad A. Toss, Michael Dabbs, David J. Regitnig, Peter Olson, Niels Wren, James H. Robinson, Carrie Corrado, Greg S. Peng, Lily H. Liu, Yun Mermel, Craig H. Steiner, David F. Chen, Po-Hsuan Cameron Commun Med (Lond) Article BACKGROUND: Breast cancer management depends on biomarkers including estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (ER/PR/HER2). Though existing scoring systems are widely used and well-validated, they can involve costly preparation and variable interpretation. Additionally, discordances between histology and expected biomarker findings can prompt repeat testing to address biological, interpretative, or technical reasons for unexpected results. METHODS: We developed three independent deep learning systems (DLS) to directly predict ER/PR/HER2 status for both focal tissue regions (patches) and slides using hematoxylin-and-eosin-stained (H&E) images as input. Models were trained and evaluated using pathologist annotated slides from three data sources. Areas under the receiver operator characteristic curve (AUCs) were calculated for test sets at both a patch-level (>135 million patches, 181 slides) and slide-level (n = 3274 slides, 1249 cases, 37 sites). Interpretability analyses were performed using Testing with Concept Activation Vectors (TCAV), saliency analysis, and pathologist review of clustered patches. RESULTS: The patch-level AUCs are 0.939 (95%CI 0.936–0.941), 0.938 (0.936–0.940), and 0.808 (0.802–0.813) for ER/PR/HER2, respectively. At the slide level, AUCs are 0.86 (95%CI 0.84–0.87), 0.75 (0.73–0.77), and 0.60 (0.56–0.64) for ER/PR/HER2, respectively. Interpretability analyses show known biomarker-histomorphology associations including associations of low-grade and lobular histology with ER/PR positivity, and increased inflammatory infiltrates with triple-negative staining. CONCLUSIONS: This study presents rapid breast cancer biomarker estimation from routine H&E slides and builds on prior advances by prioritizing interpretability of computationally learned features in the context of existing pathological knowledge. Nature Publishing Group UK 2021-07-14 /pmc/articles/PMC9037318/ /pubmed/35602213 http://dx.doi.org/10.1038/s43856-021-00013-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Gamble, Paul
Jaroensri, Ronnachai
Wang, Hongwu
Tan, Fraser
Moran, Melissa
Brown, Trissia
Flament-Auvigne, Isabelle
Rakha, Emad A.
Toss, Michael
Dabbs, David J.
Regitnig, Peter
Olson, Niels
Wren, James H.
Robinson, Carrie
Corrado, Greg S.
Peng, Lily H.
Liu, Yun
Mermel, Craig H.
Steiner, David F.
Chen, Po-Hsuan Cameron
Determining breast cancer biomarker status and associated morphological features using deep learning
title Determining breast cancer biomarker status and associated morphological features using deep learning
title_full Determining breast cancer biomarker status and associated morphological features using deep learning
title_fullStr Determining breast cancer biomarker status and associated morphological features using deep learning
title_full_unstemmed Determining breast cancer biomarker status and associated morphological features using deep learning
title_short Determining breast cancer biomarker status and associated morphological features using deep learning
title_sort determining breast cancer biomarker status and associated morphological features using deep learning
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037318/
https://www.ncbi.nlm.nih.gov/pubmed/35602213
http://dx.doi.org/10.1038/s43856-021-00013-3
work_keys_str_mv AT gamblepaul determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning
AT jaroensrironnachai determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning
AT wanghongwu determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning
AT tanfraser determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning
AT moranmelissa determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning
AT browntrissia determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning
AT flamentauvigneisabelle determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning
AT rakhaemada determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning
AT tossmichael determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning
AT dabbsdavidj determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning
AT regitnigpeter determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning
AT olsonniels determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning
AT wrenjamesh determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning
AT robinsoncarrie determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning
AT corradogregs determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning
AT penglilyh determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning
AT liuyun determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning
AT mermelcraigh determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning
AT steinerdavidf determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning
AT chenpohsuancameron determiningbreastcancerbiomarkerstatusandassociatedmorphologicalfeaturesusingdeeplearning